Obesity is the first thing you see. Don’t make it the last thing you talk about

Obesity is associated with at least 60 comorbidities, some of which can be improved through weight loss.1-4

While the majority of patients and HCPs agree that weight loss of 10% may be beneficial to their health, patients may be waiting for HCPs to take that important first step and discuss weight management.5*

*Data from a survey that examined obesity-related perceptions, attitude, and behaviors among ~3,000 adults with obesity and ~600 HCPs.

Patient sitting far away from HCP with a blurb of weight-related comorbidities

It’s time to bring obesity to the forefront

Weight-related comorbidities are just that: medical conditions that may often be associated with obesity.
Weight loss of 5% to 15% or greater may result in improvements in many of these comorbidities2:

Depression
  • Patients with obesity and depression interested in weight loss should be offered structured lifestyle intervention3
  • Weight loss of 5% to 10% may reduce the risk for emergent depression2
Obstructive sleep apnea (OSA)
  • It is estimated that nearly half of all people with obesity also have obstructive sleep apnea6
  • Weight loss of 10% or more can significantly improve apnea hypopnea index in OSA2
LEARN MORE
Gastroesophageal reflux disease (GERD)
  • Patients with obesity and GERD should be treated for weight loss. In these patients, the weight-loss goal should be 10% of body weight or greater3
Cardiovascular disease (CVD)

Obesity is associated with many common CVD risk factors, including7:

  • Hypertension
  • Dyslipidemia
  • Type 2 diabetes
LEARN MORE
Asthma/reactive airway disease
  • Patients with obesity and asthma should be treated with weight loss using lifestyle interventions but additional treatment modalities may be considered. For these patients, the weight-loss goal should be at least 7% to 8%3
Nonalcoholic fatty liver disease (NAFLD)
  • A systematic review and meta-analysis reveal that NAFLD was present in nearly 60% of patients with obesity8
  • Waist circumference—more than elevated BMI—can increase risk for NAFLD9
LEARN MORE
Urinary stress incontinence
  • Weight loss of 5% to 10% improves symptoms in men and women3
Type 2 diabetes (T2D)
  • Weight loss of 2.5% to <15% improves glycemic control; greater weight loss is associated with greater glycemic improvement2
Polycystic ovary syndrome (PCOS)
  • With a 5% to 15% weight loss, patients with obesity can improve certain PCOS symptoms, such as hyperandrogenism, oligomenorrhea, and anovulation3
LEARN MORE
Male hypogonadism
  • Weight loss of more than 5% to 10% is needed for significant improvement in serum testosterone3
Osteoarthritis (OA)
  • Weight loss of 5% to 10% improves knee functionality, pain, walking distance, and speed2
LEARN MORE
Female infertility
  • Weight loss of 2% to 5% improves ovulatory cycle, with more weight loss producing a more robust effect2
Metabolic syndrome
  • Metabolic syndrome is characterized by the concurrent presence of at least 3 of 5 specific conditions: abdominal obesity, raised triglycerides, low HDL cholesterol, elevated blood pressure, and elevated blood glucose10
Prediabetes
  • Weight loss of 2.5% to 10% can prevent diabetes in impaired glucose tolerance2
LEARN MORE
Dyslipidemia
  • Weight loss of 2.5% to <15% is associated with lower triglycerides2
  • Weight loss of 5% to <15% is associated with HDL increase (not true for BMI >40)2
Hypertension
  • Weight loss of 5% to 10% was shown to increase odds of achieving a 5 mm Hg reduction in both systolic and diastolic blood pressure in a study of 5,145 patients with overweight or obesity and type 2 diabetes11
Cancers (various)
  • 13 cancers are associated with excess weight and obesity4
  • About 40% of all cancers diagnosed in the US have been associated with overweight and obesity4

Weight loss can help improve some of your patients' weight-related comorbidities

For a deeper look into some of these conditions, tap on each weight-related comorbidity to explore the role obesity can play in your patients’ health.

Heart icon

Cardiovascular disease

LEARN MORE
Liver icon

Nonalcoholic fatty liver disease (NAFLD)

LEARN MORE
Ovaries icon

Polycystic ovary syndrome (PCOS)

LEARN MORE
Joint icon

Osteoarthritis (OA)

LEARN MORE
Blood icon

Prediabetes

LEARN MORE
Sleeping icon

Obstructive sleep apnea (OSA)

LEARN MORE
Comorbidities of obesity brochure

Comorbidities of obesity brochure

This brochure includes an overview of some common weight-related comorbidities and the impact weight loss may have on them.

DOWNLOAD

Obesity is caused by a range of factors

LEARN THE CAUSES

Patients may be waiting for HCPs to take that important first step and discuss weight management

START THE CONVERSATION

References

1. Bays HE, McCarthy W, Christensen S, et al. Obesity algorithm 2020. Presented by the Obesity Medicine Association. Accessed November 21, 2022. https://obesitymedicine.org/obesity-algorithm

2. Ryan DH, Yockey SR. Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over. Curr Obes Rep. 2017;6(2):187-194.

3. Garvey WT, Mechanick JI, Brett EM; and Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(suppl 3):1-203.

4. Cancers associated with overweight and obesity make up 40 percent of cancers diagnosed in the United States. Centers for Disease Control and Prevention. Accessed November 22, 2022. https://www.cdc.gov/media/releases/2017/p1003-vs-cancer-obesity.html

5. Kaplan LM, Golden A, Jinnett K, et al. Perceptions of barriers to effective obesity care: results from the national ACTION study. Obesity (Silver Spring). 2018;26(1):61-69.

6. Romero-Corral A, Caples SM, Lopez-Jimenez F, Somers VK. Interactions between obesity and obstructive sleep apnea: implications for treatment. Chest. 2010;137(3):711-719.

7. Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;143(21):e984-e1010.

8. Le MH, Yeo YH, Li X, et al. 2019 global NAFLD prevalence: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;20(12):2809-2817.e28.

9. Cotter TG, Rinella M. NAFLD 2020: the state of the disease. Gastroenterology. 2020;158(7):1851-1864.

10. Metabolic syndrome. Mayoclinic.org. Accessed November 24, 2020. https://www.mayoclinic.org/diseases-conditions/metabolic-syndrome/symptoms-causes/syc-20351916

11. Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Care. 2011;34(7):1481-1486.

Continue

You are now leaving the Novo Nordisk US affiliate site. Novo Nordisk is not responsible for the content of the site you are about to visit.

Continue